Preclinical study of a new (177)Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells

OBJECTIVE(S): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Asia Ocean J Nucl Med Biol
Päätekijät: Behnammanesh, Hossein, Erfani, Mostafa, Hajiramezanali, Maliheh, Jokar, Safura, Geramifar, Parham, Sabzevari, Omid, Amini, Mohsen, Mazidi, Seyed Mohammad, Beiki, Davood
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Mashhad University of Medical Sciences 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7354249/
https://ncbi.nlm.nih.gov/pubmed/32714998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/AOJNMB.2020.44432.1299
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia